SeekingAlpha · Aug 7, 2026
Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Fulgent Genetics, Inc.
FL
NASDAQ · FLGT
Fulgent Genetics, Inc.
Healthcare · Medical - Diagnostics & Research
$20.45
Up+$0.20 (+0.98%)
Updated Sep 14, 2026, 9:30 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 830.31M
- P/E ratio
- -19.35
- Dividend yield
- 0.00%
- 52-week range
- $14.04 – $21.59
- Volume
- 380.51K
- Avg. volume
- 272.77K
Price performance
FLGT price history
1M range · 19 trading sessions · Daily adjusted prices
FLGT closed at $20.45 after 19 trading sessions, up 9.59% for the selected period.
- Last close
- $20.45
- Period change
- +9.59%
- Period low
- $18.57
- Period high
- $20.45
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $20.30 | $20.52 | $19.86 | $20.45 | 380.51K |
| Sep 10, 2026 | $19.69 | $20.16 | $19.46 | $20.12 | 337.29K |
| Sep 9, 2026 | $20.09 | $20.095 | $19.61 | $19.85 | 369.94K |
| Sep 8, 2026 | $19.55 | $20.23 | $19.44 | $20.20 | 374.99K |
| Sep 4, 2026 | $19.54 | $19.86 | $19.38 | $19.73 | 225K |
| Sep 3, 2026 | $20.11 | $20.34 | $19.46 | $19.65 | 283.53K |
| Sep 2, 2026 | $19.59 | $20.1999 | $19.59 | $20.04 | 412.42K |
| Sep 1, 2026 | $19.29 | $19.85 | $19.29 | $19.59 | 285.56K |
| Aug 31, 2026 | $19.42 | $19.535 | $19.04 | $19.37 | 407.41K |
| Aug 28, 2026 | $19.88 | $19.93 | $19.49 | $19.61 | 192.54K |
| Aug 27, 2026 | $19.74 | $20.21 | $19.74 | $19.95 | 212.54K |
| Aug 26, 2026 | $19.96 | $20.00 | $19.75 | $19.81 | 170.75K |
| Aug 25, 2026 | $19.50 | $20.06 | $19.347 | $19.95 | 185.45K |
| Aug 24, 2026 | $19.89 | $19.91 | $19.19 | $19.45 | 259.92K |
| Aug 21, 2026 | $20.01 | $20.04 | $19.57 | $19.90 | 323.97K |
| Aug 20, 2026 | $19.60 | $20.52 | $19.58 | $19.92 | 203.68K |
| Aug 19, 2026 | $18.96 | $19.80 | $18.96 | $19.74 | 264.96K |
| Aug 18, 2026 | $18.49 | $18.79 | $18.38 | $18.57 | 167.97K |
| Aug 17, 2026 | $18.40 | $18.825 | $18.28 | $18.66 | 242.92K |
Latest FLGT news
The latest Smart Investors Daily articles mentioning FLGT.
Stock researchCompany · Overview
FLGT research
Overview
Company profile and research snapshot.
Company profile
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Neutral | — |
| May 5, 2026 | Piper Sandler | Neutral | — |
| Nov 11, 2025 | Piper Sandler | Neutral | — |
| Aug 5, 2025 | UBS | Buy | — |
| Aug 4, 2025 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 4, 2026
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
SeekingAlpha · Jul 31, 2026
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsMing Hsieh - Chairman & CEOBrandon PerthuisPaul Kim -...
ChartMill · Jul 30, 2026
Fulgent Genetics (NASDAQ:FLGT) Plunges 10.6% After Q2 Miss and Guidance Cut
Fulgent Genetics Q2 results missed estimates due to billing system delays, shares fell 10.6%. Full-year guidance cut, but strong cash position offers cushion.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
